Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Blonde L, Bailey TS, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M, Aroda VR.

Adv Ther. 2019 Sep;36(9):2310-2326. doi: 10.1007/s12325-019-01033-1. Epub 2019 Jul 29.

PMID:
31359368
2.

Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis.

Raccah D, Guerci B, Ajmera M, Davis K, Meyers J, Lew E, Shaunik A, Blonde L.

Endocrinol Diabetes Metab. 2019 Mar 28;2(3):e00061. doi: 10.1002/edm2.61. eCollection 2019 Jul.

3.

Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).

Bailey TS, Wu J, Zhou FL, Gupta RA, Menon AA, Berhanu P, Westerbacka J, Van Vleet J, Blonde L.

Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13818. [Epub ahead of print]

PMID:
31264346
4.

Real-world evidence in diabetes: relevance to clinical practice.

Blonde L, Bailey T, Strong J, Levin P.

J Fam Pract. 2019 Apr;68(3 Suppl). pii: jfp_6803l.

PMID:
31219479
5.

Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice.

Blonde L, Brunton SA, Chava P, Zhou R, Meyers J, Davis KL, Dalal MR, DiGenio A.

Diabetes Spectr. 2019 May;32(2):93-103. doi: 10.2337/ds17-0082.

PMID:
31168279
6.

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.

Bailey TS, Zhou FL, Gupta RA, Preblick R, Gupta VE, Berhanu P, Blonde L.

Diabetes Obes Metab. 2019 Jul;21(7):1596-1605. doi: 10.1111/dom.13693. Epub 2019 Apr 5.

7.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: Endocr Pract. 2019 Feb;25(2):204.

PMID:
30742570
8.

Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.

Blonde L, Anderson JE, Chava P, Dendy JA.

Curr Med Res Opin. 2019 May;35(5):793-804. doi: 10.1080/03007995.2018.1541790. Epub 2018 Nov 27.

PMID:
30370783
9.

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician.

Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS.

Adv Ther. 2018 Nov;35(11):1763-1774. doi: 10.1007/s12325-018-0805-y. Epub 2018 Oct 24. Review.

10.

Near field focusing by edge diffraction: publisher's note.

Boriskin A, Drazic V, Keating R, Damghanian M, Shramkova O, Blondé L.

Opt Lett. 2018 Sep 15;43(18):4501.

PMID:
30211900
11.

From Randomized Controlled Trials to the Real World: Putting Evidence into Context.

Blonde L, Dendy JA, Skolnik N, White JR Jr.

J Fam Pract. 2018 Aug;67(8 suppl):S55-S60. No abstract available.

PMID:
30137055
12.

Near field focusing by edge diffraction.

Boriskin A, Drazic V, Keating R, Damghanian M, Shramkova O, Blondé L.

Opt Lett. 2018 Aug 15;43(16):4053-4056. doi: 10.1364/OL.43.004053.

PMID:
30106950
13.
14.

Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations.

Blonde L, Dipp S, Cadena D.

Adv Ther. 2018 Jul;35(7):966. doi: 10.1007/s12325-018-0729-6.

PMID:
29949037
15.

Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.

Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L.

Diabetes Obes Metab. 2018 Sep;20(9):2148-2158. doi: 10.1111/dom.13345. Epub 2018 Jun 25.

16.

Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology.

Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L.

Diabetes Care. 2018 Jul;41(7):1327-1329. doi: 10.2337/dci18-0035. No abstract available.

PMID:
29934474
17.

Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations.

Blonde L, Dipp S, Cadena D.

Adv Ther. 2018 Jul;35(7):939-965. doi: 10.1007/s12325-018-0694-0. Epub 2018 May 18. Review. Erratum in: Adv Ther. 2018 Jun 9;:.

PMID:
29777519
18.

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.

Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B.

Diabetes Ther. 2018 Jun;9(3):1169-1184. doi: 10.1007/s13300-018-0429-x. Epub 2018 Apr 19.

19.

The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population.

Blonde L, Burudpakdee C, Divino V, Bookhart B, Cai J, Pfeifer M, Coleman CI.

Curr Med Res Opin. 2018 Aug;34(8):1501-1511. doi: 10.1080/03007995.2018.1467887. Epub 2018 May 3.

PMID:
29671627
20.

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.

Blonde L, Meneghini L, Peng XV, Boss A, Rhee K, Shaunik A, Kumar S, Balodi S, Brulle-Wohlhueter C, McCrimmon RJ.

Diabetes Ther. 2018 Jun;9(3):1347-1358. doi: 10.1007/s13300-018-0413-5. Epub 2018 Mar 29.

21.

A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.

Blonde L, Patel C, Bookhart B, Pfeifer M, Chen YW, Wu B.

Curr Med Res Opin. 2018 Jun;34(6):1143-1152. doi: 10.1080/03007995.2018.1458709. Epub 2018 Apr 20.

PMID:
29595326
22.

Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.

Montvida O, Shaw JE, Blonde L, Paul SK.

Diabetes Obes Metab. 2018 Jul;20(7):1722-1731. doi: 10.1111/dom.13288. Epub 2018 Apr 15.

PMID:
29536608
23.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17.

PMID:
29368965
24.

Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.

Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta RA, Sung J, Westerbacka J, Bailey TS, Blonde L.

Diabetes Obes Metab. 2018 May;20(5):1293-1297. doi: 10.1111/dom.13199. Epub 2018 Jan 24.

25.

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.

Home P, Calvi-Gries F, Blonde L, Pilorget V, Berlingieri J, Freemantle N.

Diabetes Obes Metab. 2018 Apr;20(4):921-929. doi: 10.1111/dom.13179. Epub 2018 Jan 7.

26.
27.

The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios.

McGill M, Blonde L, Chan JCN, Khunti K, Lavalle FJ, Bailey CJ; Global Partnership for Effective Diabetes Management.

J Clin Transl Endocrinol. 2016 Dec 9;7:21-27. doi: 10.1016/j.jcte.2016.12.001. eCollection 2017 Mar. Review.

28.

Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.

Blonde L, Marre M, Vincent M, Brette S, Pilorget V, Danchin N, Vespasiani G, Home P.

Diabetes Res Clin Pract. 2017 Nov;133:150-158. doi: 10.1016/j.diabres.2017.08.016. Epub 2017 Aug 31.

29.

Gaps and barriers in the control of blood glucose in people with type 2 diabetes.

Blonde L, Aschner P, Bailey C, Ji L, Leiter LA, Matthaei S; Global Partnership for Effective Diabetes Management.

Diab Vasc Dis Res. 2017 May;14(3):172-183. doi: 10.1177/1479164116679775. Epub 2017 Feb 1. Review.

30.

Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.

Bonadonna RC, Blonde L, Antsiferov M, Berria R, Gourdy P, Hatunic M, Mohan V, Horowitz M.

Diabetes Metab Res Rev. 2017 Sep;33(6). doi: 10.1002/dmrr.2897. Epub 2017 Jun 20.

31.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.

PMID:
28095040
32.

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.

Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L.

Cardiovasc Diabetol. 2017 Jan 13;16(1):6. doi: 10.1186/s12933-016-0490-6. Review.

33.

Diabetes Care: "Taking It to the Limit One More Time".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC.

Diabetes Care. 2017 Jan;40(1):3-6. doi: 10.2337/dc16-2326. No abstract available.

34.

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.

Blonde L, Chava P, Dex T, Lin J, Nikonova EV, Goldenberg RM.

Diabetes Obes Metab. 2017 Feb;19(2):275-283. doi: 10.1111/dom.12815. Epub 2016 Nov 29.

35.

Diabetes Care: "Lagniappe" and "Seeing Is Believing"!

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Rich SS, D'Alessio D, Riddle MC, Reynolds L.

Diabetes Care. 2016 Jul;39(7):1069-71. doi: 10.2337/dc16-0891. Epub 2016 Jun 9. No abstract available.

36.

Building Momentum: Taking on the Real “Issues” of Diabetes Care!

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Hill Golden S, Rich SS, D'Alessio D, Reynolds L.

Diabetes Care. 2016 Jan;39(1):10-12. doi: 10.2337/dc15-2315. No abstract available.

37.

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.

Patel CA, Bailey RA, Vijapurkar U, Meininger G, Blonde L.

BMC Health Serv Res. 2016 Aug 5;16(a):356. doi: 10.1186/s12913-016-1607-z.

38.

Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory".

Cefalu WT, Rosenstock J, LeRoith D, Blonde L, Riddle MC.

Diabetes Care. 2016 May;39(5):664-7. doi: 10.2337/dc16-0405. No abstract available.

39.

Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.

Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G.

Postgrad Med. 2016 May;128(4):371-80. doi: 10.1080/00325481.2016.1169894. Epub 2016 Apr 7.

PMID:
27002421
40.

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.

Vilsbøll T, Vora J, Jarlov H, Kvist K, Blonde L.

Clin Drug Investig. 2016 Apr;36(4):293-303. doi: 10.1007/s40261-016-0376-0.

41.

Individual Colorimetric Observer Model.

Asano Y, Fairchild MD, Blondé L.

PLoS One. 2016 Feb 10;11(2):e0145671. doi: 10.1371/journal.pone.0145671. eCollection 2016.

42.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE).

Endocr Pract. 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS. No abstract available.

PMID:
26731084
43.

Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme.

Montanya E, Fonseca V, Colagiuri S, Blonde L, Donsmark M, Nauck MA.

Diabetes Obes Metab. 2016 Jul;18(7):707-10. doi: 10.1111/dom.12617. Epub 2016 Feb 2. Review.

44.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE).

Endocr Pract. 2015 Dec;21(12):1403-14. doi: 10.4158/EP151063.CS.

PMID:
26642101
45.

Depth-of-Focus Affects 3D Perception in Stereoscopic Displays.

Vienne C, Blondé L, Mamassian P.

Perception. 2015;44(6):613-27.

PMID:
26489206
46.

Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.

Blonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G.

Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28.

PMID:
26373629
47.

Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!

Cefalu WT, Boulton AJ, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L.

Diabetes Care. 2015 Jul;38(7):1177-80. No abstract available.

48.

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.

Chamarthi B, Gaziano JM, Blonde L, Vinik A, Scranton RE, Ezrokhi M, Rutty D, Cincotta AH.

J Diabetes Res. 2015;2015:157698. doi: 10.1155/2015/157698. Epub 2015 Apr 28.

49.

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z.

Lancet. 2015 May 23;385(9982):2057-66. doi: 10.1016/S0140-6736(15)60936-9.

PMID:
26009229
50.

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.

Inzucchi SE, Tunceli K, Qiu Y, Rajpathak S, Brodovicz KG, Engel SS, Mavros P, Radican L, Brudi P, Li Z, Fan CP, Hanna B, Tang J, Blonde L.

Diabetes Obes Metab. 2015 Oct;17(10):956-64. doi: 10.1111/dom.12489. Epub 2015 Jun 22.

Supplemental Content

Loading ...
Support Center